News 16.03.2022 Financial highlights CHF 30.7 million cash & cash equivalents, trade and other receivables at December 31, 2021 Product sales increased more than 100% to CHF 8.3 million Received USD 6 million (CHF 5.5 million) milestone payments from Checkmate Pharmaceuticals Received USD 7 million (CHF 6.4 million) up front with USD...
News 16.03.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corporate highlights and audited financial results for 2021. Research...
Events, External events
Event date: 12.04.2022
12:10, Technopark Winterthur, Seminarraum "Weiss" / online (hybrid)
An event of Technopark Alliance at Technopark Winterthur / or via Zoom
Switzerland can continue to participate in the European research and innovation funding program Horizon Europe. The Federal Council has just decided on transitional measures for the „EIC Accelerator“ part of the program....
News 10.03.2022 Zurich-Schlieren, Switzerland, March 10, 2022 - Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that the group of Prof. J Morote Robles from the Vall d’Hebron University Hospital in Barcelona, Spain published significant new clinical study results of Proclarix® in combination with MRI for improved prostate...
News 02.03.2022 Zurich, Switzerland - 01.03.2022 Neurimmune AG has closed an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin. NI006 is designed to directly address the pathology of transthyretin amyloid cardiomyopathy (ATTR-CM) by enabling removal of amyloid fibril deposits...